A Study to Test if Fremanezumab Reduces Pain in Patients With Interstitial Cystitis-Bladder Pain Syndrome
Status:
Withdrawn
Trial end date:
2022-02-10
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the efficacy of fremanezumab in reducing
pain in patients with interstitial cystitis-bladder pain syndrome (IC-BPS).
A secondary efficacy objective of the study is to evaluate the effect of fremanezumab on
other efficacy measures, including pain, voiding frequency, urinary symptoms, and quality of
life.
And another secondary objective of the study is to evaluate the safety and tolerability of
fremanezumab administered subcutaneously in adult patients with IC-BPS.
The planned active study period is 8 weeks; the entire planned study duration for each
patient is 13 weeks.